Markers of neuroinflammation in the CSF of patients with difficult to treat psychiatric disease - Takeaways - MDSpire

Markers of neuroinflammation in the CSF of patients with difficult to treat psychiatric disease

  • By

  • Jocelyn X. Jiang

  • Artur Shvetcov

  • Nicole Fewings

  • Prudence Gatt

  • Suat Dervish

  • Justin Y Garber

  • Matthew Silsby

  • Alessandro F Fois

  • Stephen Duma

  • Sushil Bandodkar

  • Sudarshini Ramanathan

  • Andrew Bleasel

  • Bryne John

  • Ian B Hickie

  • Elizabeth M Scott

  • Anthony Harris

  • Ming-Wei Lin

  • Caitlin A. Finney

  • David A. Brown

  • May 4, 2026

  • 0 min

Share

  • 1

    The study assessed neuroinflammatory biomarkers in cerebrospinal fluid of patients with treatment-resistant psychiatric disorders.

  • 2

    Common autoantibodies found in psychiatric patients included anti-nuclear and thyroid autoantibodies, with few showing abnormal conventional CSF markers.

  • 3

    Elevated ITAC/CXCL11 levels were noted in the psychiatric cohort, while TARC/CCL17 levels were lower compared to other groups.

  • 4

    Seventeen percent of patients had CSF cytokine levels exceeding four standard deviations above the mean of non-inflammatory controls.

  • 5

    The findings suggest a subset of atypical psychiatric patients may have an immune contribution, warranting reevaluation of their diagnoses.

Original Source(s)

Markers of neuroinflammation in the CSF of patients with difficult to treat psychiatric disease

  • by Jocelyn X. Jiang, Artur Shvetcov, Nicole Fewings, Prudence Gatt, Suat Dervish, Justin Y Garber, Matthew Silsby, Alessandro F Fois, Stephen Duma, Sushil Bandodkar, Sudarshini Ramanathan, Andrew Bleasel, Bryne John, Ian B Hickie, Elizabeth M Scott, Anthony Harris, Ming-Wei Lin, Caitlin A. Finney, David A. Brown

  • May 4, 2026

Related Content

"Brain Not Right" and "Lonely in a Crowd": Unveiling the Central Architecture of Psychopathology in Obsessive-Compulsive Disorder

Can Biomarkers Refine Psych Dx?

Emerging evidence suggests biologic signals may predict treatment response and improve outcomes.

Introducing e-Motions: a novel intraoperative test for social cognition mapping. Triple validation in normative, schizophrenia, and autism spectrum disorder populations